(NASDAQ:AMD), SANTA CLARA, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) — AMD (NASDAQ: AMD) announced it will host its 2025 Financial Analyst Day on Tuesday, Nov. 11, 2025, in New York City. The event will feature presentations from AMD's executive leadership team, highlighting the company's strategy and growth opportunities, innovative product and technology roadmaps and long-term […]
(NASDAQ:TNXP), FDA PDUFA goal date of August 15, 2025, for TNXâ€'102 SL for fibromyalgia: if approved by FDA, TNXâ€'102 SL would be the first new drug for fibromyalgia in more than 16 years  In June 2025, the Company was added to the Russell 3000(R) and Russell 2000(R) Indexes following the annual reconstitution Phase 3 RESILIENT results published in peer-reviewed journal, Pain Medicine, including statistically significant reduction in
(NASDAQ:LGVN),(NASDAQ:LGVNR), MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced the closing of its previously announced public offering of 5,882,354 of the Company's Class A common stock (or pre-funded warrants
(NASDAQ:MCHP), CHANDLER, Ariz., Aug. 11, 2025 (GLOBE NEWSWIRE) — (NASDAQ:MCHP) – Microchip Technology Incorporated, a leading provider of smart, connected, and secure embedded control solutions, today announced that the Company will present at the Mizuho 2025 Technology Conference on Tuesday, August 12, 2025 at 11:30 a.m. (Mountain Time). Presenting for the Company will be Mr.
AMD to Host Financial Analyst Day on November 11, 2025 GlobeNewswire August 11, 2025 SANTA CLARA, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) — AMD (NASDAQ: AMD) announced it will host its 2025 Financial Analyst Day on Tuesday, Nov. 11, 2025, in New York City. The event will feature presentations from AMD's executive leadership team, highlighting
Longeveron Announces Closing Of Up To $17.5 Million Public Offering $5.0 million upfront with up to an additional $12.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants GlobeNewswire August 11, 2025 MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage regenerative
Microchip Technology to Present at the KeyBanc Technology Leadership Forum GlobeNewswire August 11, 2025 CHANDLER, Ariz., Aug. 11, 2025 (GLOBE NEWSWIRE) — (NASDAQ:MCHP) – Microchip Technology Incorporated, a leading provider of smart, connected, and secure embedded control solutions, today announced that the Company will present at the Mizuho 2025 Technology Conference on Tuesday, August 12,
3D Systems Reports Second Quarter 2025 Financial Results GlobeNewswire August 11, 2025 ROCK HILL, S.C., Aug. 11, 2025 (GLOBE NEWSWIRE) — 3D Systems Corporation (NYSE:DDD) announced today its financial results for the second quarter ended June 30, 2025. Revenue of $95 million led by double-digit growth in Medical Technology and Aerospace & Defense markets Regenerative
Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights GlobeNewswire August 11, 2025 FDA PDUFA goal date of August 15, 2025, for TNXâ€'102 SL for fibromyalgia: if approved by FDA, TNXâ€'102 SL would be the first new drug for fibromyalgia in more than 16 years  In June 2025, the Company was added to the Russell 3000(R) and Russell 2000(R) Indexes following the
(NASDAQ:TPST), Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in China Granted orphan drug designation from the European Medicines Agency (EMA) for amezalpat for the treatment of patients with HCC Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR